Literature DB >> 465097

Pharmacokinetic monitoring of salicylate therapy in children with juvenile rheumatoid arthritis.

L M Pachman, R Olufs, J A Procknal, G Levy.   

Abstract

Free and total (sum of free and protein bound) salicylate concentrations in serum were determined in 17 children (age: 4-17 years) with definite juvenile rheumatoid arthritis. These measurements were carried out immediately before and 2, 4, and 8 hours after the morning dose during a strict 8 hourly aspirin treatment regimen (regular tablets) started 5 days earlier. The ratio of the 0 to 8 hour total salicylate concentrations was 0.95 +/- 0.10 (mean +/- SD), indicating that steady state had been attained. The ratio of the maximum to minimum concentrations during the dosing interval ranged from 1.05 to 2.26 and decreased with increasing average concentration. The concentration ratio was less than 1.3 at average salicylate concentrations above 20 mg/100 ml. It is concluded that the timing of a blood sample is not critical for monitoring steady state serum salicylate concentrations in the usual therapeutic range if the dosing interval is 8 hours or less. Free salicylate concentrations increased more than proportionately with increasing total concentrations due to the concentration dependent protein binding of the drug in serum.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 465097     DOI: 10.1002/art.1780220804

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  10 in total

Review 1.  Medical management of children with juvenile rheumatoid arthritis.

Authors:  J T Cassidy
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

2.  Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells.

Authors:  Timothy J Zumwalt; Dominik Wodarz; Natalia L Komarova; Shusuke Toden; Jacob Turner; Jacob Cardenas; John Burn; Andrew T Chan; C Richard Boland; Ajay Goel
Journal:  Cancer Prev Res (Phila)       Date:  2017-02-02

3.  Monitoring plasma concentrations of salicylate.

Authors:  M Mandelli; G Tognoni
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of drugs used in juvenile arthritis.

Authors:  K J Skeith; F Jamali
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

5.  Clinical pharmacokinetics of salicylates: a re-assessment.

Authors:  G Levy
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

6.  Decrease of in vitro serum protein binding of salicylate in rheumatoid arthritis.

Authors:  P Netter; C Monot; M C Stalars; J M Mur; R J Royer; G Faure; J Pourel; J Martin; A Gaucher
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Apr-Jun       Impact factor: 2.441

Review 7.  Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs.

Authors:  R K Verbeeck; J L Blackburn; G R Loewen
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

8.  A comprehensive in vivo and mathematic modeling-based kinetic characterization for aspirin-induced chemoprevention in colorectal cancer.

Authors:  Tadanobu Shimura; Shusuke Toden; Natalia L Komarova; Crichard Boland; Dominik Wodarz; Ajay Goel
Journal:  Carcinogenesis       Date:  2020-07-10       Impact factor: 4.944

9.  Stability of acetylsalicylic acid in human blood collected using volumetric absorptive microsampling (VAMS) under various drying conditions.

Authors:  Seol Ju Moon; Song-Hee Han; Yong-Geun Kwak; Min-Gul Kim
Journal:  Transl Clin Pharmacol       Date:  2022-03-17

10.  Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis.

Authors:  F V N Din; M G Dunlop; L A Stark
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.